Physician Views: How will US-based endocrinologists use Eli Lilly, Boehringer Ingelheims newly approved Glyxambi?

Physician Views: How will US-based endocrinologists use Eli Lilly, Boehringer Ingelheims newly approved Glyxambi?

Code: FW-20150202 | Published: Feb-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Following a successful launch for the SGLT-2 inhibitor class - led by Johnson & Johnsons Invokana, which was approved by the FDA in March 2013 - the US diabetes market is poised to evolve further following approval of the first fixed-dose SGLT-2 inhibitor and DPP-4 inhibitor combination product: Eli Lilly and Boehringer Ingelheims Glyxambi (empagliflozin/linagliptin).

Strong uptake of the SGLT-2 class should provide a decent platform for Glyxambi, particularly as key opinion leaders (KOLs) in the diabetes space have also cited the differentiated mechanism of action, and the ability to combine with other oral diabetes classes, as a notable advantage.

Not only did Glyxambi demonstrate a statistically significant reduction in A1C versus both monotherapies at 24 weeks, but versus linagliptin monotherapy provided significant weight loss. The all-oral nature of the combination is another additional benefit, note KOLs.

When FirstWord polled US-based endocrinologists in April 2013, shortly after the approval of Invokana, 40 percent of respondents suggested that a SGLT-2/DPP-4 fixed-dose combination would be a positive development. Subsequent impressive uptake of the SGLT-2 class is likely to have reinforced this view.

Reflecting an initially cautious view among analysts towards the SGLT-2 inhibitor class, consensus forecasts for Johnson & Johnsons market-leading Invokana have risen substantially over the past year: forecast sales of around $2.2 billion in 2018 are approximately double what they were at the beginning of 2014.








Can Glyxambi ride in this slipstream and what impact will the combination have on both the SGLT-2 and DPP-4 classes? To better understand we are polling US-based endocrinologists, asking them specifically


- To what percentage of type 2 diabetes patients do you currently prescribe both a DPP-4 inhibitor and an SGLT-2 inhibitor?
- What is the likelihood that availability of Glyxambi will significantly increase your usage rate of both these drug classes in combination?
- Aside from patients already receiving both a DPP-4 inhibitor and an SGLT-2 inhibitor, from what treatment regimen will most patients you prescribe Glyxambi over the next 12 months likely transition from?
- To what percentage of eligible type 2 diabetes patients (i.e. pre-insulin) would you expect to be prescribing Glyxambi to 12 months after launch?
- What is the likelihood that availability of Glyxambi will play a significant role in slowing the progression of patients to treatment with a GLP-1 agonist?


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord